EODData

MEMBERSHIP REGISTER LOG IN

FRA, 30J: IDEAYA BIOSCIENCE DL-01

22 Dec 2025
LAST:

28.40

CHANGE:
 0.20		OPEN:
28.40		HIGH:
28.40		ASK:
0.00		VOLUME:
42
CHG(%):
0.71		PREV:
28.20		LOW:
28.40		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
22 Dec 2528.4028.4028.4028.4042
19 Dec 2528.2028.2028.2028.20105
18 Dec 2528.4028.4028.4028.40105
17 Dec 2528.6028.6028.6028.60105
16 Dec 2528.2028.2027.8027.80105
15 Dec 2528.8028.8028.0028.201.4K
12 Dec 2528.4028.4028.4028.4076
10 Dec 2529.2029.2029.2029.20135
09 Dec 2530.2030.2030.2030.20135
08 Dec 2530.6030.6030.6030.60135

PROFILE

Name:IDEAYA BIOSCIENCE DL-01
About:IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:5000 Shoreline Court, South San Francisco, CA, United States, 94080
Website:https://www.ideayabio.com
ISIN:US45166A1025
LEI:549300ULW08F62IJML11

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-7.86 
Forward P/E:-17.63 
PEG Ratio:-0.27 
Price to Sales:337.18 
Price to Book:2.45 
Operating Margin:-54.89 
Return on Assets:-0.24 
Return on Equity:-0.35 
Revenue:6.08M 
Shares:87.64M 
Market Cap:2.489B 

TECHNICAL INDICATORS

MA5:28.280.4%
MA10:28.801.4%
MA20:29.383.5%
MA50:27.264.2%
MA100:24.2317.2%
MA200:20.7137.1%
STO9:25.00
STO14:21.43
RSI14:35.90 
WPR14:-78.57
MTM14:-1.20
ROC14:-0.04 
ATR:0.61 
Week High:28.801.4%
Week Low:27.802.2%
Month High:31.009.2%
Month Low:27.8037.1%
Year High:31.009.2%
Year Low:12.82121.6%
Volatility:4.00